Cargando…
Evaluation of Nitrobenzyl Derivatives of Camptothecin as Anti-Cancer Agents and Potential Hypoxia Targeting Prodrugs
As part of our initial efforts into developing a tumor-targeting therapy, C-10 substituted derivatives of a camptothecin analog (SN-38) have been synthesized (2-, 3- and 4-nitrobenzyl) for use as potential hypoxia-activated prodrugs and evaluated for their cytotoxicity, topoisomerase I inhibition an...
Autores principales: | Liang, Dinghua, Wu, Xing, Hasinoff, Brian B., Herbert, David E., Tranmer, Geoffrey K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222813/ https://www.ncbi.nlm.nih.gov/pubmed/30111719 http://dx.doi.org/10.3390/molecules23082041 |
Ejemplares similares
-
Glutathione‐Responsive Nanoparticles of Camptothecin Prodrug for Cancer Therapy
por: Zhang, Lingpu, et al.
Publicado: (2022) -
Development of a Prodrug of Camptothecin for Enhanced
Treatment of Glioblastoma Multiforme
por: Checa-Chavarria, Elisa, et al.
Publicado: (2021) -
Design and evaluation of glutathione responsive glycosylated camptothecin nanosupramolecular prodrug
por: Li, Wenhua, et al.
Publicado: (2021) -
Reactive oxygen species activated by mitochondria-specific camptothecin prodrug for enhanced chemotherapy
por: Guo, Zhaopei, et al.
Publicado: (2022) -
Genome-Wide Transcriptional Effects of the Anti-Cancer Agent Camptothecin
por: Veloso, Artur, et al.
Publicado: (2013)